| 2026-08-07 | Press release | CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-31 | Press release | CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-30 | Press release | CareDx Announces Second Quarter 2026 Financial Results |
| 2026-07-30 | Deck | Investor presentation · Q2 2026 · Jul 2026 |
| 2026-07-30 | Press release | CareDx to Report Second Quarter 2026 Financial Results on |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| Transcript | Q2 FY26 earnings call transcript |
| 2026-07-16 | Press release | CareDx to Report Second Quarter 2026 Financial Results on |
| 2026-07-16 | Press release | CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination |
| 2026-07-07 | 8-K | Form 8-K, Item 2.01 |
| 2026-07-01 | Press release | CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology |
| 2026-06-30 | Press release | CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific |
| 2026-06-18 | Press release | CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Trans |
| 2026-06-16 | Press release | CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology |
| 2026-06-15 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-20 | Press release | CareDx to Participate in Upcoming Investor Conferences |
| 2026-05-11 | Press release | CareDx Announces Dismissal of 2021 Qui Tam Suit |
| 2026-05-01 | Press release | CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-28 | Press release | CareDx Announces First Quarter 2026 Financial Results |
| 2026-04-28 | Press release | CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing · Q1 2026 |
| 2026-04-28 | Press release | Press release · Q1 2026 · Apr 2026 |
| 2026-04-28 | Deck | Presentation of Q1 2026 |
| 2026-04-28 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-28 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-27 | Proxy | Definitive proxy statement |
| 2026-04-24 | ESG report | ESG Report of 2025 |
| 2026-04-23 | Press release | CareDx Announces Dismissal of 2021 Qui Tam Suit |
| 2026-04-23 | 8-K | Form 8-K/A, Item 5.02 |
| 2026-04-21 | Press release | CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for |
| 2026-04-20 | Press release | CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing |
| 2026-04-16 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-15 | Press release | CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Qu · Q1 2026 |
| 2026-04-14 | Press release | CareDx to Report First Quarter 2026 Financial Results on |
| Transcript | Q1 FY26 earnings call transcript |
| 2026-02-27 | Press release | CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-25 | 8-K | Form 8-K/A, Item 2.02 results |
| 2026-02-25 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-24 | Press release | CareDx Announces Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-24 | Press release | CareDx Announces Fourth Quarter and Full Year 2025 Financial Results |